HYALURONIDASE \RITUXIMAB: 619 Adverse Event Reports & Safety Profile
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
619
Total FAERS Reports
124 (20.0%)
Deaths Reported
189
Hospitalizations
619
As Primary/Secondary Suspect
108
Life-Threatening
154
Disabilities
First Report: 201204 · Latest Report: 20250909
What Are the Most Common HYALURONIDASE \RITUXIMAB Side Effects?
#1 Most Reported
Off label use
182 reports (29.4%)
#2 Most Reported
Fatigue
167 reports (27.0%)
#3 Most Reported
Drug ineffective
163 reports (26.3%)
All HYALURONIDASE \RITUXIMAB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 182 | 29.4% | 64 | 73 |
| Fatigue | 167 | 27.0% | 78 | 108 |
| Drug ineffective | 163 | 26.3% | 63 | 93 |
| Alopecia | 148 | 23.9% | 78 | 107 |
| Pain | 146 | 23.6% | 64 | 94 |
| Maternal exposure during pregnancy | 141 | 22.8% | 82 | 108 |
| Synovitis | 140 | 22.6% | 62 | 90 |
| Hypertension | 137 | 22.1% | 71 | 100 |
| Contraindicated product administered | 136 | 22.0% | 65 | 92 |
| General physical health deterioration | 136 | 22.0% | 75 | 103 |
| Hypersensitivity | 136 | 22.0% | 74 | 102 |
| Arthralgia | 135 | 21.8% | 70 | 99 |
| Abdominal discomfort | 134 | 21.7% | 77 | 105 |
| Headache | 134 | 21.7% | 63 | 93 |
| Rash | 133 | 21.5% | 63 | 66 |
| Systemic lupus erythematosus | 133 | 21.5% | 69 | 98 |
| Pemphigus | 132 | 21.3% | 68 | 97 |
| Rheumatoid arthritis | 131 | 21.2% | 67 | 85 |
| Pericarditis | 130 | 21.0% | 69 | 98 |
| Arthropathy | 129 | 20.8% | 76 | 102 |
Who Reports HYALURONIDASE \RITUXIMAB Side Effects? Age & Gender Data
Gender: 72.3% female, 27.7% male. Average age: 58.0 years. Most reports from: US. View detailed demographics →
Is HYALURONIDASE \RITUXIMAB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2012 | 2 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 5 | 4 | 4 |
| 2015 | 4 | 2 | 2 |
| 2016 | 2 | 0 | 0 |
| 2017 | 17 | 1 | 0 |
| 2018 | 25 | 1 | 5 |
| 2019 | 29 | 3 | 8 |
| 2020 | 17 | 2 | 8 |
| 2021 | 10 | 1 | 1 |
| 2022 | 13 | 3 | 3 |
| 2023 | 13 | 0 | 7 |
| 2024 | 3 | 1 | 0 |
| 2025 | 3 | 0 | 0 |
What Is HYALURONIDASE \RITUXIMAB Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 210 |
| Rheumatoid arthritis | 181 |
| B-cell lymphoma | 50 |
| Diffuse large b-cell lymphoma | 38 |
| Non-hodgkin's lymphoma | 28 |
| Follicular lymphoma | 17 |
| Mantle cell lymphoma | 15 |
| Chronic lymphocytic leukaemia | 13 |
| Lymphoma | 11 |
| Antineutrophil cytoplasmic antibody | 6 |
HYALURONIDASE \RITUXIMAB vs Alternatives: Which Is Safer?
HYALURONIDASE \RITUXIMAB vs HYALURONIDASE-ZZXF\PERTUZUMAB\TRASTUZUMAB
HYALURONIDASE \RITUXIMAB vs HYDRALAZINE
HYALURONIDASE \RITUXIMAB vs HYDRALAZINE\ISOSORBIDE DINITRATE
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE\IRBESARTAN
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE\LISINOPRIL
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE\LOSARTAN
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE\METOPROLOL
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE\NEBIVOLOL
HYALURONIDASE \RITUXIMAB vs HYDROCHLOROTHIAZIDE\OLMESARTAN MEDOXOMIL
Official FDA Label for HYALURONIDASE \RITUXIMAB
Official prescribing information from the FDA-approved drug label.